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Abstract
Background: Blood transfusions are common in cardiac surgery, but have been associated with increased
morbidity and long-term mortality. Efforts to reduce blood product use during cardiac surgery include fluid
restriction to minimize hemodilution, and protocols to guide transfusion decisions. INVOS is a modality that
monitors brain tissue oxygen saturation, and could be useful in guiding decisions to transfuse. However, the role of
INVOS (brain tissue oxygen saturation) as part of an algorithm to direct blood transfusions during cardiac surgery
has not been evaluated. This study was conducted to investigate the value of INVOS as part of a protocol for blood
transfusions during cardiac surgery.
Methods: Prospective, randomized, blinded clinical trial, on 150 (75 per group) elective cardiac surgery patients.
The study was approved by the Institution Ethics committee and all patients gave written informed consent. Data
were initially analyzed based on “intention to treat”, but subsequently were also analyzed “per protocol”.
Results: When protocol was strictly followed (“per protocol analysis”), compared to the control group, significantly
fewer patients monitored with INVOS received any blood transfusions (46 of 70 patients in INVOS group vs. 55 of
67 patients in the control group, p = 0.029). Similarly, patients monitored with INVOS received significantly fewer
units of red blood cell transfusions intraoperatively (0.20 ± 0.50 vs. 0.52 ± 0.88, p = 0.008) and overall during hospital
stay (1.31 ± 1.20 vs. 1.82 ± 1.46, p = 0.024). When data from all patients (including patient with protocol violation)
were analyzed together (“intention to treat analysis”), the observed reduction of blood transfusions in the INVOS
group was still significant (51 of 75 patients transfused in the INVOS group vs. 63 of 75 patients transfused in the
control group, p = 0.021), but the overall number of units transfused per patient did not differ significantly between
the groups (1.55 ± 1.97 vs. 1.84 ± 1.41, p = 0.288).
Conclusions: Our data suggest that INVOS could be a useful tool as part of an algorithm to guide decisions for
blood transfusion in cardiac surgery. Additional data from rigorous, well designed studies are needed to further
evaluate the role of INVOS in guiding blood transfusions in cardiac surgery, and circumvent the limitations of this
study.
Trial registration: ClinicalTrials.gov: NCT00879463
Keywords: INVOS, Cardiac surgery, Anesthesia, Transfusion, Fluid restriction, Near-infrared spectroscopy
* Correspondence: kmenelaos@yahoo.com
5Department of Anesthesiology, Washington University School of Medicine,
St. Louis, Missouri 63110, USA
Full list of author information is available at the end of the article
© 2013 Vretzakis et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Vretzakis et al. Journal of Cardiothoracic Surgery 2013, 8:145
http://www.cardiothoracicsurgery.org/content/8/1/145
Background
Cardiac surgery is associated with significant use of
blood products. Although anemia must be avoided in
these operations [1,2], data suggest that blood transfu-
sions are associated with worse outcomes [3,4], and re-
strictive transfusion practices (hemoglobin concentration
maintained between 7.0 and 9.0 g/dL) reduce organ dys-
function and cost, without adversely affecting outcome
[5,6]. A recent randomized controlled trial (RCT) in car-
diac surgery showed that a restrictive transfusion stra-
tegy targeting hematocrit 24% reduced RBC use without
increasing complications or mortality [7]. Furthermore,
the number of transfused RBC units was a risk factor for
worse outcomes and mortality in regression analysis.
Several variables associated with total red cell mass,
such as preoperative anemia, female gender and small
body size, are predictors of transfusion in cardiac surgery
[8-10]. Hematocrit and hemoglobin values are markedly
affected by positive fluid balance while on CPB without
true loss of erythrocytes. Existing guidelines underline the
importance of limiting hemodilution [11,12].
Blood transfusions based only on hematocrit value seem
unjustified in cardiac surgery. The lack of a transfusion
“threshold” and data from studies evaluating restrictive
blood transfusion strategies suggest that hematocrit alone
does not optimally support decisions to transfuse.
Monitoring of brain tissue oxygen saturation with
near-infrared spectroscopy (INVOS) is a method for
evaluating the balance of brain oxygen supply vs. con-
sumption. Published data suggest that INVOS values
have positive correlation with arterial hemoglobin
oxygen saturation, arterial pCO2 values and hemoglobin
(or hematocrit) values and negative correlation with
patient age [13,14]. The effect of anesthetic depth on
INVOS values has not been thoroughly evaluated, but
data from a small RCT have shown higher INVOS
values with deeper levels of sevoflurane or desflurane
anesthesia [15].
Our experience while conducting earlier studies and in
everyday clinical practice suggests that brain oxygen satu-
ration with near-infrared spectroscopy (INVOS) monito-
ring may help limit RBC use during CPB. The present
study was conducted to investigate the hypothesis that use
of intra-operative INVOS monitoring can reduce blood
transfusions in patients undergoing cardiac surgery under
CPB with a restrictive parenteral fluid protocol and blood
salvage techniques.
Methods
Patient selection and management
This prospective study was conducted in a tertiary care
University Hospital over a 16-month period, after
approval from the Institution Ethics committee. Written
informed consent was obtained from all patients before
entering the study. The study was registered at the www.
clinicaltrials.gov registration site, (registration number
NCT00879463).
Inclusion criteria were elective cardiac surgery under
CPB, with no age or ASA physical status classification
limit. Exclusion criteria were emergency or re-do opera-
tions, combined cardiac - carotid surgery and operations
with minimal extracorporeal flow (surgery of the ascen-
ding aorta) or circulatory arrest. Patients with hematologic
disease (including anemia requiring preoperative blood
product transfusion), coagulation abnormality, advanced
cirrhosis and renal dysfunction (creatinine >50% upper
limit of normal value) were excluded. Antiplatelet medica-
tions (except aspirin) were discontinued at least 72 hours
before surgery. Acute normovolemic hemodilution, retro-
grade autologous priming of the CPB circuit and pharma-
cologic agents to decrease blood loss were not used in any
patient.
Patients were randomly assigned to one of two groups:
Group A with intraoperative INVOS monitoring and
Group B without INVOS (control). Group assignment
originated from a sequentially numbered sealed envelope
containing a randomization code. All patients received
standardized anesthesia and intraoperative care, and
were operated by the same team (surgeon, assistants and
perfusionist) under standardized conditions with intra-
operative cell salvage. All personnel (including the surgical
team, perfusionist, nursing and ICU personnel) involved
in the care of these patients were blinded to group assign-
ment. Similarly, all investigators who collected data were
also blinded. However, the anesthesiologist in charge of
each case had access to the INVOS data and, obviously,
was not blinded.
All patients received total intravenous anesthesia with
propofol, remifentanil and cis-atracurium. Monitoring
included mixed venous oximetry plus continuous cardiac
output recording (Oximetry TD catheter, Edwards
Lifesciences, Germany) and bispectral index (BIS/XP,
Aspect Medical Systems, USA). Near-infrared spectroscopy
was used to monitor cerebro-vascular hemoglobin oxygen
saturation with the INVOS 5100 device (Somanetics,
USA) in patients assigned to group A. Anticoagulation
was achieved with heparin 300 IU/kg and Activated
Clotting Time (ACT) > 400 s was required before initia-
ting Cardiopulmonary Bypass (CPB). The CPB pump and
tubing (Stockert SIII, Germany; circuit: Custom Pack,
Dideco, Italy) were primed with 1400–2000 mls of crystal-
loid, based on patient somatometric characteristics. Pump
flow was 2.3-2.5 liter/min/m2. All patients received
antegrade blood cardioplegia. Isolated coronary artery
bypass graft (CABG) patients were operated under mild
passive hypothermia down to 33.5-34.0°C, while systemic
drift to 32.0°C was applied on all other patients. Active
rewarming to 37.5°C bladder temperature and proper
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cardiac reperfusion were applied on all patients. After
weaning from CPB, heparin was neutralized by protamine
3 mg/kg, and the remaining CPB circuit blood was washed,
centrifuged (Electa, Dideco, Italy) and re-transfused. Red
cell salvage continued until the chest was closed.
All patients, regardless of group allocation, were
treated using a restrictive parenteral fluid administration
protocol, as described in our previous study [16].
Hemodynamic instability was managed using an algo-
rithm aimed at limiting unnecessary fluid administration.
If corrective measures based on the algorithm were not
adequate, the anesthesiologist was free to act according
to his/her judgment.
All patients were admitted to the ICU postoperatively,
and received the same hypnotic-analgesic regimen
(propofol and remifentanil). INVOS monitoring was not
used in the ICU. Criteria for weaning from mechanical
ventilation included hemodynamic stability with minimal
or no catecholamine support, absence of significant
dysrhythmias, absence of major bleeding, core body
temperature > 36°C, proper level of consciousness and
acceptable arterial blood gas values with good respira-
tory mechanics. Postoperative pain was controlled with
intravenous morphine infusion. Patients were transferred
to the ward when their clinical condition and laboratory
findings were acceptable.
Perioperative RBC transfusion
Perioperative transfusion decisions were made by the at-
tending anesthesiologist. In group A (INVOS), decisions
were as follows: If mean INVOS value from both hemi-
spheres was less than 60 regardless of baseline values,
(criterion a) or INVOS decreased by 20% or more
compared to the mean value during pulmonary artery
catheter insertion (criterion b), the patient was candidate
for transfusion, but was transfused only if hematocrit
from the arterial blood-gas analysis was indicating the
need for transfusion (see below: indications in group B).
Patients with low hematocrit values who did not meet
the INVOS criteria (a or b, as described above) did not
receive blood transfusions.
In group B (control group, no INVOS) transfusion de-
cisions were based on hematocrit-based rules as follows:
During aortic cross-clamp, allogeneic blood was not
given if hematocrit was >21%. For values ≤17%, one unit
of RBC was transfused. When hematocrit was between
17-21%, anesthesiologists could decide based on their
clinical judgment. After aortic clamp removal and before
weaning from CPB (usually near the completion of the
last proximal anastomosis or during cardiac reperfusion),
RBCs were transfused for hematocrit less than 21%.
After weaning from CPB and re-transfusion of salvaged
blood, patients were transfused for hematocrit ≤24%.
In the postoperative period, fluid and blood transfu-
sion therapy was directed by the ICU staff who were
blinded to patient group assignment and were not part
of the investigator team. Consequently, while in the ICU,
patients were transfused for hematocrit ≤24%, while
transfusion decisions for hematocrit values between 24-
30% were taken after evaluation in a multimodal man-
ner, regardless of group allocation.
Data collection and statistical analysis
Sample size calculation was based on the following
assumptions: 75% of patients expected to be transfused in
the control group, with a reduction of this percentage to
50% being considered a meaningful improvement, a = 0.05
and power 0.8. Under these assumptions, the required
sample size for chi-square analysis is 57 patients per
group. However, we decided to enroll up to 75 patients
per group, in order to allow for potential problems, such
as patient attrition, missing data or protocol violations.
Hematocrit values were recorded in both groups at the
following time points: preoperatively, after arterial line
placement, after anesthesia induction, 10 minutes after
initiation of CPB, before termination of CPB, at the end
of surgery, 6 and 12 hours after admission to the ICU
and at the time of discharge from the hospital. For each
patient, IV fluids (including drug infusions and fluids
used for flushing of lines) and urine output before CPB,
during CPB and from the end of CPB until the end of
surgery were recorded. The amount of priming and
cardioplegia solutions, additional fluid given during CPB,
hemofiltration and pump residual volumes were also
recorded. Then, based on these numbers, fluid balances
were calculated for the period before CPB, during CPB
and for the entire procedure. In addition, INVOS values
were recorded for all patients assigned to group A.
While designing the study, we decided to define a cut-
off point for separating normal vs. prolonged length of
hospital stay. Data from our cardiac surgery department
showed that patients undergoing these types of proce-
dures without complications had hospital stay of 9 days
or less. Therefore, in order to minimize subjectivity
when recording complications, we defined complications
as events that required some specific acute medical
therapy or intervention resulting in prolonged (>9 days)
hospital stay or death.
Based on our earlier experience, protocol violations
were pre-defined as: A) Significant postoperative
hemorrhage leading to transfusion of more than 8
units of RBCs. B) Intraoperative disengagement from
the RBC transfusion protocol based on clinical judg-
ment. As “transfusion threshold” remains unclear for
the CPB period, the attending anesthesiologist had the
liberty to transfuse RBCs in patients where they were
concerned that, based on medical history and/or co-
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morbid conditions, peri-operative anemia could lead to
complications. C) Overall intraoperative fluid balance
greater than +1.5 L (this value was chosen because it is
greater than mean + 2SD in our previous report [16],
therefore strongly indicating that the restrictive proto-
col was not applied). D) In group A patients, when an
apparent drop of INVOS was not consistent in both
hemispheres, the patient was excluded from the proto-
col, and the anesthesiologist had to call the trial
coordinator.
Data were collected by blinded investigators and were
stored in a secure electronic database. All statistical ana-
lysis was conducted using the SPSS 15.0 for Windows
statistical software package (SPSS Inc, Chicago, IL), except
for chi-square analysis, which was conducted the Epi Info
statistical software package, which is freely available from
the CDC (Centers for Disease Control and Prevention)
website, at http://wwwn.cdc.gov/epiinfo/html/downloads.
htm.
For each patient, data were evaluated for completeness
and reliability by the study coordinator after discharge
from the hospital. Based on our hypothesis, the primary
outcome of the study was the number of RBC units
transfused during the operation. Collected data also
included transfusions in the ICU and on the ward, ICU
and hospital length of stay, morbidity and mortality, and
these data were used as secondary outcomes for compari-
sons between the two groups. Postoperative mortality was
defined as death within 30 days of discharge from the
hospital. The numbers of grafts, number of transfused
RBC units, nights in ICU and days until hospital discharge
were analyzed as continuous variables. “Transfusion” was
analyzed as a categorical variable. Normality of continuous
variables was evaluated with the Kolmogorov–Smirnov
test, and continuous variables were compared between the
two groups using the student’s two-tailed t-test. Compari-
sons of categorical variables were made using chi-square
test. P-values less than 0.05 were considered significant for
all comparisons.
After concluding the study, data from all 150 patients
were initially analyzed based on the “intention to treat”
principle. Subsequently, we also conducted data analysis
based on the “per protocol” principle, after identifying
and excluding cases of protocol violation.
Results
In total, 150 patients were enrolled, and there were no
cases of missing data. Despite occasional difficulty with
placing both BIS and INVOS sensors in group A, all
sensors were successfully applied and produced BIS and
INVOS data of adequate quality on all group A patients.
The CONSORT flowchart showing the flow of patients
through the study and data analysis is presented in
Figure 1. Demographic, clinical and perioperative data
for both groups are summarized in Table 1, and did not
differ significantly between groups. INVOS data recorded
in group A are summarized in Table 2. Hematocrit values
throughout the operation, during ICU stay and until
the day of discharge, and data on fluid balance are
shown in Table 3. Fluid balance for the entire procedure
was calculated as [(total intravenous fluids + pump prime +
total cardioplegia + anyother “ extra ” volume in theCPBma-
chine) − (total urine production + hemofiltration volume +
saver net filtration + residual CPB circuit volume)], varied
from −950 to 2550 ml in group A and from −550 to
2500 ml in group B. All variables shown on Table 3 did not
differ significantly between the two groups.
Transfusion data by group and comparison between
the groups based on “intention to treat” are summarized
in Table 4. In total, 254 units of RBCs were transfused in
150 patients. Intraoperatively, fewer group A (INVOS)
patients received fewer RBC units, and the difference
was statistically significant (p = 0.04). Overall, 51 of 75
patients (68%) received transfusions in the INVOS group
vs. 63 of 75 patients (84%) in the control group, and this
difference was highly significant (p = 0.021). Hematocrit
indication was present in 20 (26.6%) group A patients
(all during CPB). Transfusion criterion a (mean INVOS
value less than 60%) was present in 37 patients and
criterion b (INVOS ≥20% decrease) in 27 patients.
Among these patients, both criteria were present in 20
patients, not necessarily the same as those showing
hematocrit indication for transfusion. In total, 14
patients in this group were transfused receiving 18 units
of RBCs (Table 4). Hematocrit indication was present in
21 (28.0%) patients in group B, and the proportion of
patients who met the hematocrit indication for transfu-
sion did not differ significantly between the two groups
(p = 0.854). These patients were transfused along with 4
more (see below: protocol violations) receiving in total 40
units of RBCs.
There were no OR deaths in either group. Duration of
mechanical ventilation, ICU length of stay (LOS) and
hospital LOS did not differ significantly between groups
(Table 1). Fifty-one patients (68.0%) in group A and 41
patients (54.7%) in group B stayed in the hospital for
more than 9 days, but most of these patients did not
exhibit any pre-defined complication. In group A compli-
cations included: a) one patient for MVR/CABG= signifi-
cant postoperative hemorrhage and valve dysfunction,
emergency re-operation, transfusion of 15 units of RBCs,
death in ICU in the 3rd day, b) ventilation time >24 h in 9
patients (3 patients were re-intubated for low cardiac out-
put syndrome, 3 patients showed difficult and delayed
weaning from mechanical ventilation, 1 patient required
dialysis, 1 patient developed neurologic deficit delaying
extubation but with good course, 1 patient was re-
intubated for cardiac arrest during removal of thoracic
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drains and was re-explored), c) MI in 2 patients, and d)
arrhythmias requiring treatment in 3 patients. In group B
complications were: a) one patient was re-intubated for
arrhythmia, hemodynamic instability, increase of hepatic
enzymes and finally he died, b) ventilation time >24 h in 6
patients (1 patient was re-intubated for pneumothorax
and low cardiac output syndrome, 1 patient for MI and
low cardiac output syndrome, 1 patient for re-exploration
for bleeding, 3 patients showed difficult and delayed
weaning from mechanical ventilation), c) MI in 2 patients,
d) arrhythmia requiring treatment in 2 patients, e)
hemodynamic instability with cognitive dysfunction in 1
patient and f) treatment for hypertension delaying dis-
charge in 1 patient. The overall mortality in this study was
2 deaths in 150 patients.
In total, protocol violations were identified for 13
patients (8.7%). Five of them were noted in group A
(6.6%): a) one patient received 15 units of RBCs and
finally died, b) two patients undergoing CABG received
transfusions even though they did not meet criteria for
transfusion according to our protocol, c) one patient
undergoing CABG was intraoperatively transfused after
meeting all (INVOS and hematocrit) criteria, but
received parenteral fluids to a positive balance of
2550 ml, c) one patient undergoing CABG met criteria
for transfusion but fluid balance positive by over 1.5 L.
The protocol was violated in 8 group B patients (10.6%):
a) one patient undergoing CABG was transfused under
hematocrit indication but had postoperative fluid bal-
ance > +1.5 L; b) three patients undergoing CABG and
one patient undergoing MVR were transfused without
meeting the hematocrit indication (and all of them with
positive fluid balance > 1.5 L) and c) three patients (one
undergoing AVR/CABG and two undergoing CABG) did
not receive transfusions, but had positive fluid balance
>1.5 L.
After excluding cases of protocol violation, statistical
analysis “per protocol” showed that, compared to the
control group, significantly fewer group A patients
received any blood transfusion, both intraoperatively (11
of 70 patients in group A vs. 20 of 67 patients in the
control group, p = 0.048) and during the entire
hospitalization (46 of 70 patients in group A vs. 55 of 67
patients in the control group, p = 0.029). Similarly,
The CONSORT E-Flowchart 
Assessed for eligibility 
(n=170)
Excluded (n=20)
















1) 1 pt received 15 units RBCs
2) 2 pts were transfused without 
transfusion criteria
3) 2 pts had fluid balance >1.5 L
8 Protocol violations
All 8 pts had fluid balance > 1.5L
Of those: 
1) 1 pt was transfused based on 
hematocrit indication but had fluid 
balance >1.5 L
2) 4 pts were transfused without 
hematocrit indication
3) 3 pts had fluid balance >1.5 L
Group A (n=70) Group B (n=67)Analysis 
“Per Protocol
Figure 1 CONSORT flowchart showing the flow of patients through the study and data analysis.
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compared to the control group, the total number of
RBCs transfused per patient was significantly lower in
the INVOS group intraoperatively (0.20 ± 0.50 units per
patient in the INVOS group vs. 0.52 ± 0.88 units per
patient in the control group, p = 0.008), and during the
entire hospitalization (1.31 ± 1.20 units per patient in the
INVOS group vs. 1.82 ± 1.46 units per patient in the
control group, p = 0.024). Of note, because the number
of patients transfused and the number of RBC units
transfused per patient did not differ between groups dur-
ing ICU stay, the overall lower RBC use in the INVOS
group seems to be the result of reduced intraoperative
RBC use, while the INVOS-based protocol was in effect.
Results of a per protocol analysis of our transfusion data
(after excluding cases of protocol violation) are presented
in Table 5.
Discussion
Transfusion of RBC and other blood components in
common in cardiac surgery, due to several reasons, in-
cluding pre-existing anemia, intraoperative hemodilution
and intraoperative or postoperative blood loss, even in
otherwise uncomplicated surgery. However, even though
transfusions are clearly necessary in many cases, blood
product use has been associated with increased morbid-
ity [4] and long-term mortality [3] in cardiac surgery,
and therefore attempts to reduce blood transfusions may
contribute to reduced complications and improved
outcomes. Consequently, several measures have been
evaluated in an attempt to reduce blood transfusions
during cardiac surgery [12], including tolerating lower
Table 1 Demographic and clinical data by group
Group A Group B P
(INVOS, n = 75) (Control, n = 75)
Age (yrs) 67.3 ± 8.5 65.9 ± 9.5 0.329
Female n (%) 12 (16.0%) 15 (20.0%) 0.523
Weight (kg) 79.1 ± 14.4 75.9 ± 13.0 0.140
Height (cm) 166.9 ± 8.3 166.7 ± 8.9 0.893
BMI 28.4 ± 4.6 27.2 ± 3.5 0.084
BSA (m2) 1.86 ± 0.19 1.83 ± 0.20 0.281
LVEF (%) 47.4 ± 10.8 48.3 ± 8.0 0.536
Prior MI, n (%) 42 (56.0%) 40 (53.3%) 0.742
Diabetes, n (%) 17 (22.6%) 19 (25.3%) 0.702
Hypertension, n (%) 62 (82.6%) 59 (78.6%) 0.535
COPD, n (%) 16 (21.3%) 16 (21.3%) 1.000
Preoperative Hct (%) 39.5 ± 3.90 40.4 ± 4.53 0.246
Operation
CABG (isolated), n (%) 63 (84.0%) 58 (77.3%) 0.348
Number of grafts 207 in 67 pts 192 in 66 pts
MVR, n (%) 3 (4.0%) 3 (4.0%)
MVR/CABG, n (%) 1 (1.3%) 0 (0.0%)
AVR, n (%) 5 (6.6%) 4 (5.3%)
AVR/CABG, n (%) 3 (4.0%) 8 (10.6%)
ASD repair, n (%) 0 (0.0%) 2 (2.6%)
CPB time (min) 88.8 ± 18.2 93.7 ± 29.8 0.216
Operation time (min) 249.9 ± 41.9 248.0 ± 59.2 0.812
Postoperative data
hmv* 16.4 ± 24.7 14.6 ± 10.3 0.558
ICU LOS** 2.7 ± 3.8 2.7 ± 3.6 0.999
hospital LOS*** 10.9 ± 3.6 10.2 ± 10.7 0.181
LOS > 9◊, n (%) 51 (68.0%) 41 (54.7%) 0.132
Complications, n (%) 14 (18.6%) 12 (16.0%) 0.666
Death, n (%) 1 (1.3%) 1 (1.3%) 1.000
* hmv hours of mechanical ventilation (ICU).
** ICU length of stay in nights.
*** Hospital LOS in days (not including days in hospital before surgery).
◊ denotes the number of patients with hospital LOS greater than 9 days.
Table 2 Intraoperative INVOS values (group A)
Before induction During line insertion “Worse” on CBP
Side R L R L R L
Min 47 47 38 43 36 37
Max 93 85 89 93 80 81
Mean 66.56 66.29 70.44 70.87 58.29 58.63
SD 7.31 7.48 8.65 9.28 7.89 8.22
Table 3 Hematocrit values, intravenous fluids and fluid
balance by group
Hematocrit values (%) Group A Group B P
(INVOS, n = 75) (Control, n = 75)
Preoperative 39.54 ± 3.90 40.38 ± 4.53 0.246
After arterial line placement 38.45 ± 4.32 38.68 ± 4.40 0.765
After anesthesia induction 38.19 ± 4.61 37.84 ± 4.53 0.655
After first cardioplegia 20.20 ± 3.60 20.16 ± 3.83 0.947
End of CPB 23.07 ± 3.45 23.26 ± 3.03 0.721
End of operation 27.55 ± 4.18 27.50 ± 4.15 0.943
6 hours in the ICU 28.15 ± 3.38 28.79 ± 3.32 0.263
12 hours in the ICU 28.61 ± 3.77 29.29 ± 3.58 0.254
Day of discharge 30.67 ± 3.07 31.28 ± 2.58 0.193
Fluid balance (ml)
IV fluids to initiation of CPB 368.5 ± 177.0 416.4 ± 184.6 0.101
Urine to initiation of CPB 110.8 ± 95.9 135.7 ± 127.6 0.164
Fluid balance
After 1st cardioplegia 2240.2 ± 238.8 2326.0 ± 306.4 0.055
Urine output during CPB 666.2 ± 594.0 694.0 ± 423.0 0.743
Total urine output 1326.2 ± 842.2 1419.3 ± 690.7 0.452
Use of filter, n (%) 8 (10.6%) 9 (12.0%) 0.796
Overall fluid balance 685.4 ± 784.1 809.9 ± 651.1 0.290
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hemoglobin values [5] and restricting parenteral fluids in
order to avoid hemodilution [16]. Studies evaluating the
effectiveness of restrictive fluid administration strategies in
mitigating the precipitous intraoperative hematocrit drop,
rather than restrictive blood transfusion strategies, are
scarce. We recently reported that, compared to liberal
fluid administration, a restrictive parenteral fluid protocol
significantly reduced intraoperative red blood cell
(RBC) transfusions [17]. We also showed in a later RCT
that restrictive fluid strategies may be more beneficial in
patients prone to transfusion because of low preoperative
hematocrit, female sex, or small BSA [16]. In both studies,
re-infusion of washed blood from the thoracic cavities was
used to reduce the need for transfusion. However, we
faced difficulty defining a transfusion “threshold” in these
studies, because existing reports raise concerns regarding
safety when tolerating low hematocrit values [18,19].
Because INVOS reflects the balance of site-specific
oxygen delivery vs. consumption, it is plausible to
consider INVOS a reasonable monitor for adequacy of
oxygen tissue delivery. Furthermore, because there is a
positive correlation between INVOS and hemoglobin con-
centration [13], it is reasonable to interpret low INVOS
values as evidence that hemoglobin or hematocrit values
are not sufficient for maintaining adequate oxygen delivery
to tissues, and therefore the patient needs to be transfused.
Similarly, adequate INVOS values could be considered as
indicator of adequate oxygen delivery, and therefore as re-
assurance that transfusion of red blood cells is not needed.
However, data on the use of INVOS as tool for decision
making with regards to blood transfusion during cardiac
surgery are, to our knowledge, very limited, and we believe
there is a need for rigorous assessment of this technology
in cardiac surgery and perhaps in other types of major
surgery.
The main finding of this prospective, randomized
study was the significantly reduced intraoperative and
overall need for transfusion of RBCs in patients under-
going elective cardiac surgery, with use of a hematocrit
and INVOS-supported algorithm to guide the decision
to transfuse, and the observed differences between the
two groups were significant both in the “intention to
treat”. Significant findings derived from “intention to
treat” analysis are generally preferred, because results
based on the “intention to treat” principle better reflect
“real life” conditions, whereby errors in judgment and
deviations from established protocols invariably occur.
We believe that, our findings are worth reporting,
because they suggest that, under optimal conditions
(“per protocol analysis”) and in real-life conditions
(“intention to treat” analysis), the use of INVOS to assist
with decision-making regarding blood transfusions could
be of value, and therefore deserves further study. In
addition, we believe it is worth noting that the overall
lower RBC use in group A (the INVOS group) was the
result of reduced RBC use intraoperatively (while the
INVOS-based protocol was in effect). Therefore, it may
be reasonable to speculate that the observed overall
differences between the two groups could be greater if
the INVOS-protocol were applied in the ICU as well.
Clearly, this is just a hypothesis, but we think this
hypothesis deserves to be evaluated in a formal study.
Strengths of our study include study design (prospective,
randomized, blinded), the inclusion of a well defined
Table 5 Transfusion data (“per protocol” analysis,
protocol violations excluded)
Group A (n = 70) Group B (n = 67) P
In OR
RBC units transfused 14 35
Patients transfused 11 (15.7%) 20 (29.8%) 0.048
RBC per transfused pt 1.27 ± 0.47 1.75 ± 0.55 0.021
RBC/pt overall 0.20 ± 0.50 0.52 ± 0.88 0.008
In the ICU and ward
RBC units transfused 78 87
Patients transfused 42 (60.0%) 49 (74.2%) 0.103
RBC per transfused pt 1.86 ± 0.72 1.78 ± 1.04 0.670
RBC/pt overall 1.11 ± 1.07 1.30 ± 1.25 0.344
Overall
RBC units transfused 92 122
Patients transfused 46 (65.7%) 55 (82.1%) 0.029
RBC per transfused pt 2.00 ± 0.89 2.22 ± 1.21 0.314
RBC/pt overall 1.31 ± 1.20 1.82 ± 1.46 0.024
Table 4 Transfusion data by group (analysis based on
“intention to treat”)
Group A (n = 75) Group B (n = 75) P
In OR
RBC units transfused 18 40
Patients transfused 14 (18.6%) 25 (33.3%) 0.040
RBC per transfused pt 1.29 ± 0.47 1.60 ± 0.58 0.090
RBC/pt overall 0.24 ± 0.54 0.53 ± 0.84 0.011
In the ICU and ward
RBC units transfused 98 98
Patients transfused 47 (62.6%) 57 (76.0%) 0.076
RBC per transfused pt 2.09 ± 2.05 1.71 ± 1.01 0.239
RBC/pt overall 1.31 ± 1.91 1.31 ± 1.20 1.000
Total
RBC units transfused 116 138
Patients transfused 51 (68.0%) 63 (84.0%) 0.021
RBC per transfused pt 2.27 ± 2.01 2.19 ± 1.17 0.781
RBC/pt overall 1.55 ± 1.97 1.84 ± 1.41 0.288
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patient population, with clearly defined criteria for trans-
fusion. In addition, when protocol was properly followed,
reduction of RBC use was highly significant, and the ob-
served difference between groups was clinically meaning-
ful. Furthermore, the use of a restrictive intravenous fluid
administration policy on all patients probably resulted in
overall reduction of transfusion requirements in both
groups, due to avoidance of hemodilution before and
during CPB. Consequently, it is plausible that the observed
differences between the groups, and therefore the per-
ceived benefit from using INVOS as tool to guide transfu-
sion decisions could be more pronounced in settings
where fluid restriction is not used, and therefore overall
transfusion requirements are higher.
Disadvantages of the study include the significant
number of cases with protocol violations; this is prob-
ably the reason why data analysis based on “intention to
treat” did now show a significant difference with regards
to overall number of RBC units transfused per patient
between the INVOS and the control group. Conse-
quently, our results also demonstrate that it is difficult
to conduct clinical studies in the complex operating
room and ICU environment utilized for cardiac surgery,
and, despite efforts to avoid them, study protocol viola-
tions can still occur. Therefore, researchers and study
coordinators need to pay particular attention and closely
monitor such studies in an attempt to minimize protocol
violations and therefore generate more valid data.
Conclusions
This prospective randomized clinical study suggests that
the use of cerebral oximetry (INVOS) as part of an algo-
rithm to guide RBC transfusions can result in significant
reduction of RBC use in patients undergoing elective
cardiac surgery, when the established protocol for fluid
restriction and decision to transfuse is properly followed.
However, the observed benefit is no longer significant
when protocol violations are included in the analysis
(“intention to treat” analysis). We suggest that, based on
these results, INVOS could be a useful tool for monitor-
ing patients during cardiac surgery, but data from well
designed clinical trials with rigorous attention to study
protocol, in an attempt to minimize protocol violations
are needed to better assess the validity of our findings.
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